Short Interest in Dermata Therapeutics, Inc. (NASDAQ:DRMA) Increases By 28.3%

Dermata Therapeutics, Inc. (NASDAQ:DRMA) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 409,394 shares, a growth of 28.3% from the January 15th total of 319,014 shares. Based on an average trading volume of 3,466,499 shares, the short-interest ratio is presently 0.1 days. Approximately 17.7% of the company’s shares are short sold. Approximately 17.7% of the company’s shares are short sold. Based on an average trading volume of 3,466,499 shares, the short-interest ratio is presently 0.1 days.

Dermata Therapeutics Stock Down 4.4%

Shares of DRMA traded down $0.06 during trading on Monday, reaching $1.29. The company’s stock had a trading volume of 171,083 shares, compared to its average volume of 1,866,691. The company has a market cap of $3.66 million, a price-to-earnings ratio of -0.17 and a beta of 0.54. The company has a fifty day moving average of $2.21 and a two-hundred day moving average of $3.75. Dermata Therapeutics has a twelve month low of $1.29 and a twelve month high of $23.70.

Dermata Therapeutics (NASDAQ:DRMA) last posted its quarterly earnings results on Friday, November 14th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.59) by ($0.06).

Analysts Set New Price Targets

A number of research analysts have commented on DRMA shares. Wall Street Zen upgraded Dermata Therapeutics to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (e)” rating on shares of Dermata Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dermata Therapeutics stock. Clear Street Group Inc. acquired a new stake in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned about 0.60% of Dermata Therapeutics as of its most recent SEC filing. 8.67% of the stock is currently owned by hedge funds and other institutional investors.

About Dermata Therapeutics

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.